[A20-20] Apalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V
Last updated 02.06.2020
Project no.:
A20-20
Commission:
Commission awarded on 25.02.2020 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Patients with metastatic hormone-sensitive prostate cancer
For patients in good general condition: hint of non-quantifiable added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A20-36 | Apalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A19-09 | Apalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A20-62 | Apalutamide (prostate cancer) - Addendum to Commission A20-20 | Commission completed |
Federal Joint Committee (G-BA)
2020-08-20: G-BA decision was published.